Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

August 2020; 6 (4) Clinical/Scientific NotesOpen Access

GLUT1 deficiency

Retinal detrimental effects of gliovascular modulation

Matt Henry, John Kitchens, Juan M. Pascual, Ramiro S. Maldonado
First published June 25, 2020, DOI: https://doi.org/10.1212/NXG.0000000000000472
Matt Henry
From the University of Kentucky College of Medicine (M.H.); Retina Associates of Kentucky (J.K.), Lexington; Rare Brain Disorders Program (J.M.P.), Department of Neurology and Neurotherapeutics, Department of Physiology (J.M.P.), Department of Pediatrics (J.M.P.), Eugene McDermott Center for Human Growth & Development/Center for Human Genetics (J.M.P.), The University of Texas Southwestern Medical Center, Dallas; and Ophthalmic Genetics Program (J.K., R.S.M.), Department of Ophthalmology, University of Kentucky, Lexington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Kitchens
From the University of Kentucky College of Medicine (M.H.); Retina Associates of Kentucky (J.K.), Lexington; Rare Brain Disorders Program (J.M.P.), Department of Neurology and Neurotherapeutics, Department of Physiology (J.M.P.), Department of Pediatrics (J.M.P.), Eugene McDermott Center for Human Growth & Development/Center for Human Genetics (J.M.P.), The University of Texas Southwestern Medical Center, Dallas; and Ophthalmic Genetics Program (J.K., R.S.M.), Department of Ophthalmology, University of Kentucky, Lexington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan M. Pascual
From the University of Kentucky College of Medicine (M.H.); Retina Associates of Kentucky (J.K.), Lexington; Rare Brain Disorders Program (J.M.P.), Department of Neurology and Neurotherapeutics, Department of Physiology (J.M.P.), Department of Pediatrics (J.M.P.), Eugene McDermott Center for Human Growth & Development/Center for Human Genetics (J.M.P.), The University of Texas Southwestern Medical Center, Dallas; and Ophthalmic Genetics Program (J.K., R.S.M.), Department of Ophthalmology, University of Kentucky, Lexington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramiro S. Maldonado
From the University of Kentucky College of Medicine (M.H.); Retina Associates of Kentucky (J.K.), Lexington; Rare Brain Disorders Program (J.M.P.), Department of Neurology and Neurotherapeutics, Department of Physiology (J.M.P.), Department of Pediatrics (J.M.P.), Eugene McDermott Center for Human Growth & Development/Center for Human Genetics (J.M.P.), The University of Texas Southwestern Medical Center, Dallas; and Ophthalmic Genetics Program (J.K., R.S.M.), Department of Ophthalmology, University of Kentucky, Lexington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
GLUT1 deficiency
Retinal detrimental effects of gliovascular modulation
Matt Henry, John Kitchens, Juan M. Pascual, Ramiro S. Maldonado
Neurol Genet Aug 2020, 6 (4) e472; DOI: 10.1212/NXG.0000000000000472

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
385

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Most patients with glucose transporter type 1 (GLUT1) deficiency syndrome (G1D) experience anticonvulsant-refractory epilepsy and abnormal cognitive and motor development.1 Ninety percent of patients with G1D harbor a causative loss-of-function mutation in the SLC2A1 gene; in the others, brain fluorodeoxyglucose (FDG) PET can confirm the diagnosis.

G1D investigation has centered on the cerebral aspects of the disease, but extracerebral manifestations are plausible.1 The eye is a likely substrate: retinal GLUT1 sustains ocular glucose transport based on its expression in Müller, vascular endothelial, and pigmentary epithelial cells. Notably, GLUT1 is a target for diabetic retinopathy drugs.2,3 We describe retinal abnormalities in a patient with G1D in the broader context of the plausible mechanisms and consequences of retinal GLUT1 loss of function or therapeutic inhibition.

Case report

A 20-year-old woman with the common epileptic form of G1D reported subnormal visual acuity uncorrectable with glasses and harbored a de novo pathogenic SLC2A1 variant (c.1454C>T; P485L).1,4 The mutation introduced a dileucine motif in GLUT1 associated with clathrin recruitment and excessive internalization of cell membrane GLUT1.5

Her visual acuity was 20/40 (OD) and 20/30 (OS) with no other obvious ocular abnormalities. Optical coherence tomography (OCT) revealed retinal thinning in the posterior pole respecting the fovea (figure 1, A and B) and absence of the interdigitation band peripherally with moderate photoreceptor layer thinning (figure 1, C and D). Swept source OCT demonstrated significant choroidal thickening (571 and 495 μm in the OD and OS, respectively; normal for age: ∼330–400 μm). Retinal fundus autofluorescence (FAF) demonstrated hyperautofluorescence outside the fovea and an unusual hyperautofluorescence in the central fovea (figure 1, E and F). OCT-angiography (OCTA) showed a paucity of perimacular vessels (figure 1, G and H).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Retinal multimodal imaging in a patient with GLUT1 deficiency

(A and B) Optical coherence tomography (OCT) total macular color thicknessmaps (in microns) showing marked retinal thinning (blue-purple area) outside the fovea in the right and left eyes, respectively. (C and D) OCT b-scans at the foveal centers demonstrate thickened retinal pigment epithelial layer interdigitation bands (red arrows) only at the foveal centers; the bands disappear in the periphery of the scans. (E and F) Wide-field fundus autofluorescence (FAF) images of the right and left eye, respectively, showing increased FAF in the perifoveal area corresponding to the area of retinal thinning depicted in (A and B). Note that the fovea demonstrates subtle but abnormal hyperautofluorescence centrally; this area normally shows hypoautofluorescence because of macular pigment AF blockage. (G and H) OCT angiography (OCTA) of the superficial capillary plexus demonstrates decreased perimacular vessel density. (A–F) See figure e-2 (links.lww.com/NXG/A276) for comparison of all images to those of a normal subject.

There were functional correlates to these findings, including multiple D-15 Farnsworth color testing defects in the protan axis bilaterally and suppressed cone flicker amplitudes with normal rod system electroretinography (ERG) responses (figure e-1, links.lww.com/NXG/A276). Repeat testing over 1 year was invariant.

Discussion

Our patient with G1D exhibited structural and functional retinal dysfunction. The retinal changes were congruent across all imaging modalities: the retinal thinning noted on macular color thickness maps correlated with the hyperautofluorescence on FAF and with the area of reduced vessel density on OCTA. Together with the thickened choroid and decreased cone flicker, the simplest interpretation of our findings is early onset photoreceptor degeneration.

In the retina, Glut1-mediated transport occurs across capillary endothelial cells of the inner blood-retinal barrier and the retinal pigment epithelium (RPE). This implies that our patient's de novo somatic (and therefore uniformly vascular and glial because there is no reason to suspect mosaicism) mutation exerts secondary consequences on neurons (which are largely devoid of GLUT1). This likely stems from reduced glucose (or another mediator) flux across retinal cell types.

Modest GLUT1 expression changes are functionally relevant: increased renal GLUT1 has deleterious consequences in diabetic nephropathy.6 Conversely, GLUT1 small interfering RNAs (siRNAs) reduce retinal glucose and ameliorate diabetic retinopathy, which is accompanied by reduced ERG signal amplitude and outer nuclear layer thinning.3 This is analogous to our patient's diminished cone flicker amplitude and retinal thickness. Furthermore, diabetic mice exhibit increased RPE GLUT1 expression after prolonged exposure to hyperglycemia and hypoxia. The resulting elevated RPE glucose can be associated with impaired pigment epithelium-derived (PEDF) secretion, leading to imbalanced vascular endothelial growth factor (VEGF)/PEDF and stimulated neovascularization.3 Our patient exhibited reduced capillary density, which may reflect altered VEGF/PEDF release as in diabetic retinopathy.

Some diabetic retinopathy therapies target GLUT1, including angiotensin-converting enzyme inhibitors such as captopril. This occurs, in part, via decreased retinal glucose after the reduction of GLUT1-mediated glucose transport (despite unaltered GLUT1 expression). Intraocular siRNA diminishes GLUT1 expression in the inner blood-retinal barrier of streptozotocin-diabetic mice and decreases retinal glucose.3 Last, GLUT1 inhibition by forskolin or genistein in diabetic mice leads to similar results. In all these contexts, retinal glucose decreases after treatment, suggesting that GLUT1 inhibition can counteract the end result of multifactorial diabetic retinopathy.

However, GLUT1 inhibition may be detrimental to photoreceptor and RPE cells. In mice, reduction of RPE glucose via GLUT1 knockout results in outer segment shortening, photoreceptor cell death, and Müller cell activation. This underscores the importance of near-constant GLUT1 activity in the retina.7 Our findings suggest that these experimental observations are likely relevant in humans, suggesting that therapeutic GLUT1 inhibition may result in undesired effects.

Conclusions

Our case demonstrates the contribution of nonneural GLUT1 to retinal cell (including photoreceptor) activity and vision. Although diabetic retinopathy therapies that inhibit GLUT1 are plausible, this inhibition may be detrimental. This case also illustrates the value of retinal assessment in G1D and in those receiving GLUT1-related diabetes therapies.

Study funding

Supported by Glut1 Deficiency Foundation.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NG for full disclosures.

Acknowledgment

The authors acknowledge the collaboration of the patient described and her legally consenting family. The support of the Glucose Transporter Type 1 Deficiency Foundation and of the NIH (grant NS077015 to J.M.P.) is also acknowledged.

Appendix Authors

Table
Table

Footnotes

  • The Article Processing Charge was funded by The GLUT1 Foundation.

  • Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

  • Received January 16, 2020.
  • Accepted in final form June 1, 2020.
  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Pascual JM,
    2. Ronen GM
    . Glucose transporter type I deficiency (G1D) at 25 (1990–2015): presumptions, facts, and the lives of persons with this rare disease. Pediatr Neurol 2015;53:379–393.
    OpenUrl
  2. 2.↵
    1. Calado SM,
    2. Alves LS,
    3. Simao S,
    4. Silva GA
    . GLUT1 activity contributes to the impairment of PEDF secretion by the RPE. Mol Vis 2016;22:761–770.
    OpenUrl
  3. 3.↵
    1. You ZP,
    2. Zhang YL,
    3. Shi K, et al
    . Suppression of diabetic retinopathy with GLUT1 siRNA. Sci Rep 2017;7:7437.
    OpenUrlCrossRef
  4. 4.↵
    1. Slaughter L,
    2. Vartzelis G,
    3. Arthur T
    . New GLUT-1 mutation in a child with treatment-resistant epilepsy. Epilepsy Res 2009;84:254–256.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Meyer K,
    2. Kirchner M,
    3. Uyar B, et al
    . Mutations in disordered regions can cause disease by creating dileucine motifs. Cell 2018;175:239–253.e17.
    OpenUrl
  6. 6.↵
    1. Heilig CW,
    2. Liu Y,
    3. England RL, et al
    . D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 1997;46:1030–1039.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Swarup A,
    2. Samuels IS,
    3. Bell BA, et al
    . Modulating GLUT1 expression in retinal pigment epithelium decreases glucose levels in the retina: impact on photoreceptors and Muller glial cells. Am J Physiol Cell Physiol 2019;316:C121–C133.
    OpenUrlCrossRef

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case report
    • Discussion
    • Conclusions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology Genetics: 8 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise